Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphangioleiomyomatosis × Resveratrol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 2 Colonic Neoplasms 2 Unspecified Adult Solid Tumor, Protocol Specific 1 Rectal Neoplasms 1 Polycystic Ovary Syndrome 1 Neuroendocrine Tumors 1 Neoplasms 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Follicular 1 Lymphangioleiomyomatosis 1 Liver Neoplasms 1 Gastro-enteropancreatic neuroendocrine tumor 1 Chemoprevention 1 Carcinoma, Hepatocellular 1

Interventions

Sirolimus 10 Everolimus 4 Imatinib Mesylate 2 temsirolimus 1 saracatinib 1 carbon-11 acetate 1 Valproic Acid 1 Urination 1 Sugars 1 Simvastatin 1 Resveratrol 1 Respiratory Function Tests 1 Phlebotomy 1 Octreotide 1 Loratadine 1 Letrozole 1 Immunoglobulin G 1 Hydroxychloroquine 1 Genetic Testing 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Celecoxib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03253913 2023-02-01

RESULT

University of Cincinnati

Phase 2 Completed

25 enrolled 11 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡